FEDERAL COURT OF AUSTRALIA
Eli Lilly & Company v Pfizer Ireland Pharmaceuticals (No 2) [2004] FCA 850
INTELLECTUAL PROPERTY – privilege of registered patent attorneys – whether extending to communications with patent attorneys not registered in Australia
WORDS AND PHRASES – “registered patent attorney”
Patents Act 1990 (Cth), s 200(2)
Federal Court Rules O 33 r 12Wilden Pump Engineering Co v Funfeld [1985] FSR 159 at 168 applied
Pfizer Pty Ltd v Warner Lambert Pty Ltd (1989) 24 FCR 47 applied
Kennedy v Wallace [2004] FCA 332 at [57] referred toELI LILLY AND COMPANY & ORS V PFIZER IRELAND PHARMACEUTICALS & ANOR (No 2)
V604 OF 2002HEEREY J
30 JUNE 2004
MELBOURNE
IN THE FEDERAL COURT OF AUSTRALIA
VICTORIA DISTRICT REGISTRY
V604 OF 2002
BETWEEN:
ELI LILLY AND COMPANY
FIRST APPLICANT/FIRST CROSS-RESPONDENTELI LILLY AUSTRALIA PTY LTD (ACN 000 233 992)
SECOND APPLICANT/SECOND CROSS-RESPONDENTELI LILLY AND COMPANY LIMITED
THIRD APPLICANT/THIRD CROSS-RESPONDENTAND:
PFIZER IRELAND PHARMACEUTICALS
FIRST RESPONDENT/FIRST CROSS-CLAIMANTPFIZER PTY LIMITED (ACN 008 422 348)
SECOND RESPONDENT/SECOND CROSS-CLAIMANTJUDGE:
HEEREY J
DATE OF ORDER:
30 JUNE 2004
WHERE MADE:
MELBOURNE
THE COURT ORDERS THAT:
- The respondents/ cross-claimants produce to the applicants/ cross-respondents the documents identified as items 1 and 2 in the Notice to Produce dated 24 June 2004
- The respondents/ cross-claimants pay the applicants/ cross-respondents’ costs of today’s hearing.
Note: Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.
IN THE FEDERAL COURT OF AUSTRALIA
VICTORIA DISTRICT REGISTRY
V604 OF 2002
BETWEEN:
ELI LILLY AND COMPANY
FIRST APPLICANT/FIRST CROSS-RESPONDENTELI LILLY AUSTRALIA PTY LTD (ACN 000 233 992)
SECOND APPLICANT/SECOND CROSS-RESPONDENTELI LILLY AND COMPANY LIMITED
THIRD APPLICANT/THIRD CROSS-RESPONDENTAND:
PFIZER IRELAND PHARMACEUTICALS
FIRST RESPONDENT/FIRST CROSS-CLAIMANTPFIZER PTY LIMITED (ACN 008 422 348)
SECOND RESPONDENT/SECOND CROSS-CLAIMANT
JUDGE:
HEEREY J
DATE:
30 JUNE 2004
PLACE:
MELBOURNE
REASONS FOR JUDGMENT
The applicants/cross-respondents Eli Lilly and Company and Eli Lilly Australia Pty Ltd (collectively Lilly) have given a notice to produce under O 33 r 12 of the Federal Court Rules requiring production of the following documents which have been discovered by the respondents/cross-claimants Pfizer Ireland Pharmaceuticals and Pfizer Pty Limited (collectively Pfizer):
“1.Document entitled ‘Record of inventorship UK Patent Application No 9311920.4’ (identified in the Respondent’s discovery as PIP.3229.0001) from N.Terett and P. Ellis dated 22 June 1993;
2.Document entitled ‘Request for Patent Application – The use of cGMP PDE inhibitors for impotence’ (identified in the Respondent’s discovery as PIP.3229.0002) dated 18 January 1993;”
Pfizer has resisted production on the basis that the documents were brought into existence for the dominant purpose of obtaining advice from its in-house patent attorneys in the United Kingdom. In the course of argument senior counsel also relied on what he said was a “cloak of confidentiality analogous to privilege”.
Section 200(2) of the Patents Act 1990 (Cth) (the Act) provides:
“(2) A communication between a registered patent attorney and the attorney’s client in intellectual property matters, and any record or…
Keep reading for free
Create a free CaseChat account to read Eli Lilly and Company v Pfizer Ireland Pharmaceuticals (No 2... and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2004] FCA 850
- Decision Date
CaseChat Overview and Summary
The primary legal issue was whether the respondents were required to disclose the documents identified in the Notice to Produce. The court had to determine the extent of disclosure obligations under the Australian Patent Act and the relevant case law. Another aspect considered was whether the respondents had legitimate grounds to resist disclosure based on confidentiality or privilege.
The court found that the documents in question were pertinent to the patent validity and infringement issues at hand. It held that the respondents were obliged to produce the documents as they were relevant to the proceedings. The court rejected the respondents' argument that the documents were subject to legal professional privilege. The Federal Court ordered the respondents to produce the specified documents and to pay the costs of the hearing.
Orders
Orders of the court
1. The respondents/ cross-claimants produce to the applicants/ cross-respondents the documents identified as items 1 and 2 in the Notice to Produce dated 24 June 2004
2. The respondents/ cross-claimants pay the applicants/ cross-respondents’ costs of today’s hearing.
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
Established by: HEEREY J